Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan;63(1):140–146. doi: 10.2967/jnumed.120.259325

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

PMC Copyright notice

FIGURE 6. — (A) ¹⁸F-FAraG PET/CT and ¹⁸F-FAraG PET/CT overlaid on T2-weighted (T₂w) MR images from untreated and fingolimod-treated animals at W7–14dpi. Graph shows quantification of ¹⁸F-FAraG signal in entire brain, corpus callosum, hippocampus, and cortex. (B) T1-weighted (T₁w) and T2-weighted MR images of fingolimod-treated and untreated mice and corresponding quantification of T1-enhancing lesions and normalized T2-weighted signal intensity of corpus callosum, hippocampus and cortex. (C) Immunofluorescence images of corpus callosum for CD3 T cells (green), microglia/macrophages (Iba1, red), and myelin (MBP, orange) from untreated and fingolimod-treated mice at W7–14dpi. Graphs show quantification of immunofluorescence images from corpus callosum, hippocampus, and cortex. ID = injected dose. *P ≤ 0.05. **P ≤ 0.01. ****P ≤ 0.0001.